HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on Allogene Therapeutics (NASDAQ:ALLO) but has reduced the price target from $12 to $10.

January 19, 2024 | 11:38 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Allogene Therapeutics' Buy rating is maintained by HC Wainwright & Co., but the price target is lowered from $12 to $10.
The reduction in the price target by HC Wainwright & Co. suggests a downward revision of the firm's expectations for Allogene Therapeutics' stock performance, which could lead to a negative short-term impact on the stock price. However, the maintenance of a Buy rating indicates the analyst's overall positive outlook on the company, which might mitigate some negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100